New research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting shows that the targeted radionuclide alpha therapy, ²²⁵Ac-DOTATATE, has long-term anti-tumor effects against advanced gastroenteropancreatic #neuroendocrinetumors (GEP-NETs). This study won the SNMMI Abstract of the Year Award. “²²⁵Ac-DOTATATE is a promising therapy option that adds a new dimension to the treatment of end-stage GEP-NETs, especially for patients who have tried all other standard therapy options,” Dr. Bal said. “These results warrant a phase 3, randomized, controlled trial to assess the true efficacy of ²²⁵Ac-DOTATATE versus ¹⁷⁷Lu-DOTATATE.” Chandrasekhar S. Bal, Department of Nuclear Medicine and PET at the All India Institute of Medical Science in New Delhi, India. Read the article >>